Second, they also contribute to the targeted delivery of IFN-β that could improve tumor elimination through various mechanisms including improving DCs’ cross-priming functionality, suppressing Treg activation and expansion, and disturbing the microvasculature of the tumor (177). The gene discussed is IFNB1; the disease is neoplasm.